Edition 2026-11 · 244 drugs · components, not a score
The OmniRx Access Index: one dated row per drug, shown as its components
Each row joins what public records say about one drug: Medicare Part D spending, FDA label supplements and recalls, assistance programs, safety programs, schedules and Medicaid use. There is no combined score, because any single number would hide the judgment that belongs to the reader. Every cell is computed from the public dossier files, so you can recompute it.
Download
access-index.csv · access-index.json (the same rows, the column dictionary, the edition root). Edition root: 006ab9a329709cbe, checkable on the editions page. An empty cell means the dossier holds no fact for that component, which is not zero.
What the rows hold: 17% name at least one REMS program (released ones included), 23% are listed by at least one assistance program, 31% have an FDA recall on record, and 95% have Medicaid state figures.
The twelve largest by Part D spending
| Drug | Part D gross spending | Label supplements, non-manufacturing | Recalls | Assistance programs | REMS | DEA schedule |
|---|---|---|---|---|---|---|
| Eliquis | $20,775 million | 20 | 1 | 4 | listed | |
| Ozempic | $12,970 million | 43 | 4 | 4 | ||
| Jardiance | $11,436 million | 22 | 2 | 2 | ||
| Mounjaro | $6,337 million | 12 | ||||
| Xarelto | $6,232 million | 32 | 3 | |||
| Trulicity | $5,454 million | 21 | 3 | 1 | listed | |
| Trelegy Ellipta | $5,294 million | 9 | 2 | 1 | ||
| Farxiga | $5,291 million | 20 | ||||
| Revlimid | $4,180 million | 37 | 5 | in force: 1 | ||
| Entresto | $4,020 million | 4 | ||||
| Januvia | $3,808 million | 28 | 1 | listed | ||
| Biktarvy | $3,456 million | 13 | 3 |
Part D spending is gross, before manufacturer rebates; it is not a net cost and not a price a patient pays. The full table is in the download.
Column dictionary
Each column names where it comes from in the dossier and what it does not mean.
| Column | Label | Source in the dossier | Does not mean |
|---|---|---|---|
slug | Slug | file name of the dossier | the page and dossier address of the drug |
drug | Drug | dossier query | a name, not an identifier |
group | Group | negotiated = in the CMS negotiated-price file; medicines = outside it, ranked by Part D demand | a page family, not a clinical class |
applications | FDA applications | identity.application_numbers | every application the name resolved to, joined with a semicolon |
part_d_year | Part D year | spending.latest_year | the newest year CMS reports |
part_d_gross_spending_usd | Part D gross spending (USD) | spending.series, latest year | before manufacturer rebates; not a net cost and not a patient price |
part_d_claims | Part D claims | spending.series, latest year | claims for all manufacturers combined; not a formulary or coverage statement |
part_d_beneficiaries | Part D beneficiaries | spending.series, latest year | people with at least one claim; not a measure of need |
negotiated_effective | Negotiated price effective | price.negotiated_scheduled.effective | the date CMS lists; a deselected row is not a scheduled price |
negotiated_over_pharmacy_cost | Negotiated price over pharmacy cost (ratio) | price.median_negotiated_over_nadac | a median across compared packages; not a price a patient pays |
label_events_total | FDA label supplements | label_history.events_total | a dated list of supplements; not a reading of what changed |
label_events_non_cmc | FDA label supplements, non-manufacturing | label_history.non_cmc_events | supplements that are not chemistry, manufacturing and controls |
recalls_total | FDA recalls | recalls.recalls_total | FDA classifies hazard, not the effect on supply |
generic_entry_first | Generic entry upper bound, earliest | generic_entry[].date | an upper bound from listed dates, not a forecast of launch |
generic_entry_last | Generic entry upper bound, latest | generic_entry[].date | an upper bound from listed dates, not a forecast of launch |
assistance_programs | Assistance programs listing the drug | assistance_and_offers.programs_listing_this_drug | a listing is not a decision about any person |
manufacturer_offers | Manufacturer offers recorded | assistance_and_offers.manufacturer_offers | none recorded does not mean none exists |
biologic_status | Biologic status | biologic_status.products[].status | what the Purple Book lists; not a forecast of substitution |
biosimilars_listed | Biosimilars listed | biologic_status.products[].biosimilars_listed | what the Purple Book names against the reference product |
rems_programs | REMS programs named | rems.programs | includes released programs |
rems_in_force | REMS programs in force | rems.programs[].in_force | a released REMS is not in force |
dea_schedule | DEA schedule | controlled_schedule.ingredients[].schedules | a federal classification; not a statement about access |
orphan_designations | Orphan designations | orphan_designation.ingredients[].designation_count | a designation is not an approval |
safety_notice_date | Newest FDA safety notice | safety_communication.notices[].issued | the notice as FDA published it, listed unchanged; not interpreted |
medicaid_states_with_data | States with Medicaid figures | medicaid_state_utilization.states_with_data | a state without figures was suppressed or unreported, not zero |
medicaid_reimbursed_usd | Medicaid reimbursed, all states (USD) | medicaid_state_utilization.all_states_medicaid_reimbursed_usd | before manufacturer rebates; fee-for-service only where the publisher suppresses managed care; not a net cost |
medicaid_prescriptions | Medicaid-paid prescriptions, all states | medicaid_state_utilization.all_states_medicaid_paid_prescriptions | understates use where managed-care cells are suppressed |
sections_held | Dossier sections held | count of sections in the dossier | how much the library holds for the drug, not how good the drug is |
Method and limits
The Index is derived only from the files under /api/v1/dossier/. It holds the drugs that have a page here: those in the CMS negotiated-price file and those outside it that rank high in Medicare Part D demand and pass the data gate. It is US data, a reference layer and not clinical advice. Drug shortage state is not a column yet. Use the integration guide to build it into a product, or the licence page for terms.
Questions
What is the OmniRx Access Index?
One dated row per drug that lists its access components as separate columns: Medicare Part D spending, FDA label supplements and recalls, assistance programs, REMS safety programs, DEA schedule and Medicaid use. It is never combined into one score.
Why is there no single score?
A single number would hide a judgment that belongs to the reader. Each cell is computed from the public dossier files, so anyone can recompute it.
Does an empty cell mean zero?
No. An empty cell means the dossier holds no fact for that component, which is not the same as zero.
Where can I download the Index?
The CSV and JSON files are linked at the top of this page with a column dictionary and the edition root, so the rows can be checked against a published edition.